219 related articles for article (PubMed ID: 1574995)
1. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Tedroff J; Aquilonius SM; Hartvig P; Bredberg E; Bjurling P; Långström B
Acta Neurol Scand; 1992 Feb; 85(2):95-102. PubMed ID: 1574995
[TBL] [Abstract][Full Text] [Related]
2. What has PET told us about Parkinson's disease?
Aquilonius SM
Acta Neurol Scand Suppl; 1991; 136():37-9. PubMed ID: 1801535
[TBL] [Abstract][Full Text] [Related]
3. Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography.
Tedroff J; Aquilonius SM; Laihinen A; Rinne U; Hartvig P; Anderson J; Lundqvist H; Haaparanta M; Solin O; Antoni G
Acta Neurol Scand; 1990 Jan; 81(1):24-30. PubMed ID: 2330812
[TBL] [Abstract][Full Text] [Related]
4. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
[TBL] [Abstract][Full Text] [Related]
5. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
6. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J
Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
9. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
10. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
11. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
12. Estimation of regional cerebral utilization of [11C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography.
Tedroff J; Aquilonius SM; Hartvig P; Lundqvist H; Bjurling P; Långström B
Acta Neurol Scand; 1992 Mar; 85(3):166-73. PubMed ID: 1574997
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Chase TN; Engber TM; Mouradian MM
Adv Neurol; 1993; 60():181-5. PubMed ID: 8420133
[No Abstract] [Full Text] [Related]
14. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
Hwang WJ; Yao WJ; Wey SP; Shen LH; Ting G
Eur Neurol; 2002; 47(2):113-7. PubMed ID: 11844900
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
16. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Torstenson R; Tedroff J; Hartvig P; Fasth KJ; Långström B
J Cereb Blood Flow Metab; 1999 Oct; 19(10):1142-9. PubMed ID: 10532639
[TBL] [Abstract][Full Text] [Related]
17. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
[TBL] [Abstract][Full Text] [Related]
18. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.
Hartvig P; Agren H; Reibring L; Tedroff J; Bjurling P; Kihlberg T; Långström B
J Neural Transm Gen Sect; 1991; 86(1):25-41. PubMed ID: 1751027
[TBL] [Abstract][Full Text] [Related]
19. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease.
Tedroff J; Aquilonius SM; Hartvig P; Lundqvist H; Gee AG; Uhlin J; Långström B
Acta Neurol Scand; 1988 Mar; 77(3):192-201. PubMed ID: 3259784
[TBL] [Abstract][Full Text] [Related]
20. Dopamine autoreceptor function is lost in advanced Parkinson's disease.
Ekesbo A; Rydin E; Torstenson R; Sydow O; Låengström B; Tedroff J
Neurology; 1999 Jan; 52(1):120-5. PubMed ID: 9921858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
